Monday, October 6, 2014

Sheraton Hotel
Birmingham Ballroom
2101 Richard Arrington Jr. Boulevard North
Birmingham, Alabama

Personalized Cancer Care

Program Committee
Eddy Yang, MD, PhD Chair
Jonas Almeida, PhD
Andres Forero, MD
Bruce Korf, MD, PhD
Kevin Roth, MD, PhD

Meeting Coordinator
Susan Winn



Donald A. Berry, Ph.D.

University of Texas MD Anderson Cancer Center

Donald Berry is Professor of Biostatistics at the University of Texas MD Anderson Cancer Center. Under his guidance, as founding chair and head of the Division of Quantitative Sciences, quantitative science has grown rapidly to become a leader in the development and use of innovative statistical methodology, robust statistical design for clinical trials, bioinformatics, and computational biology. Dr. Berry has extensive experience in the adaptive clinical trial design, where data obtained during the trial are used to guide changes in the trial midstream.  He is the co-principal investigator of the I-SPY2 trial, where specific drug-biomarker combinations are evaluated to identify subpopulation of patients who will benefit from these therapies.

Mark S. Boguski, M.D., Ph.D.

Genome Health Solutions, Harvard Medical School and Beth Israel Deaconess Medical Center

Mark Boguski is the Founder and Chief Medical Officer of Genome Health Solutions, Inc.  He also serves on the faculty of Harvard Medical School at the Center for Biomedical Informatics and in the Department of Pathology at Beth Israel Deaconess Medical Center where he founded the Genomic Medicine Initiative in 2009. Dr. Boguski is a pioneer in the fields of bioinformatics and genomics and has previously held faculty positions at the Johns Hopkins University School of Medicine, the U.S. National Institutes of Health, the U.S. National Library of Medicine and as an executive in the biotechnology and pharmaceutical industries. He is a former vice president of Novartis and a Visionary and Influencer according to the Personalized Medicine Coalition. Boguski is an elected member of the Institute of Medicine of the U.S. National Academies, the American College of Medical Informatics and the College of American Pathologists. He is a graduate of the Medical Scientist Training Program at Washington University in St. Louis.

Paul Haluska, Jr., M.D., Ph.D.

Mayo Clinic

Paul Haluska is Associate Professor of Oncology and Assistant Professor of Pharmacology at the Mayo Clinic. He is co-Director of the Phase I Program and member of the Womenís Cancer Program of the Mayo Clinic Cancer Center. His research interests focus on developing orthotopic patient derived xenografts (or ĎAvatarsí) to develop novel therapeutics and individualize therapy for patients with ovarian cancer. He also is a leading expert in the development of novel therapeutics targeting IGF signaling in breast and other cancers.

Mark G. Kris, M.D.

Memorial Sloan Kettering Cancer Center

Mark G. Kris is an Attending Physician in the Thoracic Oncology Service at Memorial Hospital, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. He is the first incumbent of the William and Joy Ruane Chair in Thoracic Oncology. Dr. Kris is a Professor of Medicine at the Weill Cornell Medical College. Since 2012, he has served as the Lead Physician for the Memorial Sloan Kettering - IBM Watson Collaboration.

Dr. Kris graduated from Fordham University. After receiving his medical degree from Weill Cornell Medical College, he served as Chief Medical Resident and Fellow in Medical Oncology at Memorial Sloan Kettering Cancer Center.

He is author or coauthor of over 280 original scientific publications. Dr. Kris holds memberships in the American Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer. He is a member of the guideline panels on non-small cell lung cancers and antiemetics for the National Comprehensive Cancer Center Network. He served as co-chair of the American Society of Clinical Oncology guideline panel for adjuvant chemotherapy and radiation for non-small cell lung cancers. He serves on the Antiemetic Guideline Panel for the American Society of Clinical Oncology. He is a Fellow of the American College of Physicians, The American College of Chest Physicians, and The American Society of Clinical Oncology. He received the first American Society of Clinical Oncology Humanitarian Award in 2011. Dr. Kris also received the Annie Blount Storrs Award from Calvary Hospital 2014.

Dr. Kris is a specialist in lung cancers and other tumors arising in the chest. He is particularly interested in developing strategies to choose treatments for patients based on molecular characteristics of their tumor specimens. His research also includes the evaluation of new anticancer agents (particularly those targeting lung cancers), multimodality therapy (using surgery, radiation and drugs together to improve outcomes for individuals with thoracic cancers), and the training of the IBM Watson cognitive computer to assist physicians in choosing the best treatments for their patients with cancers.

Phillip J. Buckhaults, Ph.D.

University of Alabama at Birmingham

Phillip Buckhaults is Associate Professor of Medicine in the Division of Hematology and Oncology at the University of Alabama at Birmingham and a Scientist in the UAB Comprehensive Cancer Center. His research interests are the functional genomics of early-onset epithelial cancers, with particular emphasis on germline variants in the TP53 gene that contribute to disparate incidence and early age of diagnosis in people of African ancestry.

Christopher D. Willey, M.D., Ph.D.

University of Alabama at Birmingham

Christopher Willey is Associate Professor of Radiation Oncology at the University of Alabama at Birmingham and a Scientist in the UAB Comprehensive Cancer Center. He has secondary faculty appointments within the Cell, Developmental and Integrative Biology Department, the Biochemistry and Molecular Genetics Department, as well as the Biomedical Engineering Department. His research interests include signal transduction, particularly with kinase driven cascades, and radiation response pathways in a variety of cancers, including gliomas, lung cancer, urological cancers, breast cancers, and head and neck cancers. In the area of kinase signaling, Dr. Willey is the Director of the UAB Kinome Core that performs global kinase signaling analysis using a high-content peptide substrate microarray platform. This facility has been used for molecular profiling/subtyping and to identify and examine kinase drivers involved in several disease processes ranging from autoimmune disease, psychiatric illness, and numerous cancers. The UAB Kinome Core has been a featured tool for studies involving Glioblastoma multiforme patient-derived xenografts, which are being used for biomarker testing and drug development.